双成药业(002693) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥84,781,750.41, representing a year-on-year increase of 164.39%[3] - The net profit attributable to shareholders was ¥15,943,078.67, an increase of 176.31% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥15,149,596.72, up 168.35% year-on-year[3] - The net profit attributable to the parent company increased by 93.33% year-on-year, driven by the sales profit from the new product[8] - The company's operating profit for the current period was -7,394,530.37, an improvement from -51,330,965.44 in the previous period, indicating a significant reduction in losses[25] - The total profit for the current period was -7,538,875.32, compared to -51,363,813.55 in the previous period, reflecting a substantial decrease in overall losses[25] - The net profit attributable to the parent company's shareholders was -2,523,479.07, a notable improvement from -37,837,689.22 in the previous period[25] Cash Flow - The net cash flow from operating activities increased by 262.79% year-to-date, totaling ¥32,081,773.07[3] - Cash inflow from operating activities totaled 191,244,462.63, compared to 151,475,766.86 in the previous period, showing a year-over-year increase[27] - Cash outflow from operating activities was 159,162,689.56, down from 171,182,964.84 in the previous period, indicating improved cash management[27] - The net cash flow from investing activities was -51,390,022.73, worsening from -16,061,574.38 in the previous period[27] - The net cash flow from financing activities was 2,614,710.40, a significant decrease from 69,322,933.39 in the previous period[27] - The ending cash and cash equivalents balance was 28,699,487.14, down from 37,070,882.11 in the previous period, reflecting a decline in liquidity[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥797,770,471.93, a 1.77% increase from the end of the previous year[3] - The company's total assets increased to ¥797,770,471.93 from ¥783,866,026.52, reflecting a growth of 1.15%[22] - Total liabilities rose to ¥393,424,894.74 from ¥372,260,377.26, marking an increase of 5.1%[22] - The total equity attributable to shareholders decreased to ¥390,893,020.73 from ¥393,409,970.88, a decline of 0.4%[22] - Cash and cash equivalents decreased to ¥28,699,487.14 from ¥45,105,842.30, a drop of 36.2%[20] - Inventory increased to ¥85,659,863.26 from ¥80,535,394.02, an increase of 6.6%[20] - The company’s investment properties decreased to ¥15,493,180.48 from ¥17,597,890.39, a decline of 11.97%[20] Operating Costs and Expenses - The company reported a 33.04% increase in total operating income year-on-year, primarily due to the sales of the newly listed product, paclitaxel injection (albumin-bound)[7] - The cost of goods sold increased by 43.79% year-on-year, attributed to the higher production costs of the new product[7] - Research and development expenses decreased by 39.76% year-on-year, reflecting reduced investment in research activities[8] - Research and development expenses decreased to ¥6,040,736.81 from ¥10,028,401.53, a reduction of 39.6%[24] - Total operating costs decreased slightly to ¥180,108,046.32 from ¥180,496,024.50, with operating costs specifically rising to ¥73,115,398.25 from ¥50,847,128.40, indicating a significant increase of 43.8%[24] - The company experienced a 391.31% increase in non-operating expenses year-on-year, mainly due to increased losses from fixed asset disposals[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,166[12] - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.92% of the shares, totaling 136,516,546 shares[12] Investment Activities - Investment cash inflows decreased by 55.19% compared to the same period last year, primarily due to a reduction in the recovery of financial investments[10] - Cash paid for investments decreased by 46.30% year-on-year, mainly due to a reduction in financial investments during the reporting period[10] - Net cash flow from investment activities decreased by 219.96% compared to the same period last year, primarily due to a decrease in net cash flow from financial investments[10] - Cash received from investment increased by 262.67% year-on-year, mainly due to an increase in stock subscription payments during the reporting period[10] Audit Status - The company has not undergone an audit for the third quarter financial report[29]